Bioxcel Therapeutics Inc (BTAI) - News Archive

In a compelling demonstration of resilience and strategic acumen, BioXcel Therapeutics, Inc. (Nasdaq: BTAI) has announced the successful completion of its registered direct offering, raising gross proceeds of approximat...

BioXcel Therapeutics Regains Nasdaq Compliance, Eyes Future Growth Amid Significant Stock SurgeNew Haven, Conn. BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence t...

BioXcel Therapeutics Adjusts Course Amid Phase 2a Trial and Financial FluctuationsIn a recent financial disclosure, Bioxcel Therapeutics Inc. reported a notable improvement in its operating loss for the quarter, with fi...

BioXcel Therapeutics, an innovative biopharmaceutical company, is making significant strides in the treatment of two distinct health challenges: acute agitation associated with bipolar disorders and schizophrenia, as we...

BioXcel Therapeutics, a leading innovator in the pharmaceutical industry, recently released an announcement regarding the preliminary estimated unaudited second-quarter net revenues generated from sales of their highly...

:This article provides a comprehensive assessment of the recent topline results from BioXcel Therapeutics post-marketing requirement study on the use of IGALMI (dexmedetomidine) Sublingual Film for the treatment of agit...

BioXcel Therapeutics, proud pioneers in Artificial Intelligence and neuroscience, has recently shared news about a late-breaking abstract based on the preliminary results from the Phase 2 trial. A collaboration between...

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialBioXcel Therapeutics, a clinical-stage biopharmaceutical company focused on drug development utilizing arti...

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer s DementiaCompany plans to initiate trial following recent meeting with FDAIn a signific...

BioXcel Therapeutics Announces $25 Million Registered Direct OfferingNEW HAVEN, Conn., March 25, 2024 - BioXcel Therapeutics, Inc. (Nasdaq: BTAI) made a significant announcement today regarding a registered direct offer...

In a recent press release, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a pioneering biopharmaceutical company specializing in neuroscience and immuno-oncology, shocked the industry by announcing the termination of its pr...

BioXcel Therapeutics, a clinical-stage biopharmaceutical company, has achieved an important milestone in its investigator-sponsored Phase 2 relapsed pancreatic cancer trial. The firm announced the completion of patient...